Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — JP Morgan 43rd Annual Healthcare Conference 2025
33 slides from Telix Pharmaceuticals's conference presentation, Jan 13, 2025
Slide 1: Defining the Future of Radiopharma
FAPi therapy (TLX400) in metastatic medullary thyroid cancer Defining the Future of Pre- treatment Radiopharma JP Morgan 43rd Annual Healthcare Conference, 12-16 January 2025 NASDAQ: TLX | ASX: TLX Post- treatment
Slide 2: Disclaimer
Disclaimer This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our we
Slide 3: Company Overview
Company Overview XN
Slide 4: Theranostics are the future of oncology
Theranostics are the future of oncology A powerful way to tackle cancer “See It, • Highly-targeted • Patient-centric TLX400 therapy: Patient with breast cancer demonstrating significant tumor mass reduction2 Treat It” • Personalized Before Tx After TLX101 Therapy: Patient with glioblastoma, TLX101-C
Slide 5: Telix: A unique company
Telix: A unique company We are leading the theranostic medicine modality The only pure-play radiopharmaceutical company with: Strong commercial record Deep theranostic pipeline – Manufacturing, isotope and FY2024 revenue: US$517M – multiple near-term catalysts distribution partnerships 55% increase
Slide 6: Commercial performance
Commercial performance Full year guidance - beat Total revenue US$M +55% Year over year growth FY2024 Total revenue US$142 (unaudited)1 US$135 US$125 US$115 US$517M US$97 Up 55% from US$333M in FY2023 Guidance FY2024: US$490 million to Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 US$510 million 1. FY2024
Slide 7: 2025 Roadmap
2025 Roadmap Clear strategy, multiple near-term value drivers Commercial portfolio and Late-stage therapeutic Advancing “next generation” Patient confidence from geographic expansion pipeline radiopharmaceuticals world-class manufacturing Preparing for multi-product Focus on urology, Harnessing the
Slide 8: The immediate opportunity
The immediate opportunity High unmet medical need, significant value creation Prostate cancer Kidney cancer Brain Total U.S. market opportunity1 Px Tx Px Tx Px Tx TLX591 TLX250 TLX101 TLX592 TLX252 TLX102 US$21.5B US$4.6B Px US$3.3B Px US$0.8B US$ US$16.9B 12.1B Px US$ US$0.5B Tx US$8.8B 6.8B Tx US$
Slide 9: Therapeutics Platform
Therapeutics dy Platform On ie
Slide 10: Therapeutics strategy
Therapeutics strategy Multiple near-term catalysts and next-generation assets Prostate RCC, other Brain, other cancer CAIX1-expressing tumors rare cancers Progress β TLX591 β TLX250 β TLX101 multiple Potential first radiolabelled Potential first-in-class Potential first systemic late-stage antibody
Slide 11: Late-stage pipeline
Late-stage pipeline Clinically-validated programs, targeting three assets in pivotal trials in 2025 Targeting Isotope Phase 1 Phase 2 Phase 3 Catalysts agent Prostate 177Lu ProstACT GLOBAL Ph3 trial in Antibody TLX591 (177Lu rosopatamab tetraxetan) PSMA1 progress, Part 1 readout H1 2025 Kidney STARL
Slide 12: Early-stage pipeline
Early-stage pipeline The “next generation” of products Targeting Isotope R&D Pre-clinical Clinical (Ph 0/1) agent Prostate 225Ac Antibody (alpha) TLX592 (225Ac-RADmAb®) PSMA Kidney + CALL OUT BOX other 225Ac Antibody (alpha) TLX252 (225Ac-girentuximab) CAIX Brain 211At Small molecule (alpha) TLX102
Slide 13: TLX591: A highly differentiated approach to PSMA therapy
TLX591: A highly differentiated approach to PSMA therapy Potential to overcome limitations of small molecule approach Negligible exocrine TLX591 biodistribution (SPECT imaging)3 gland uptake Promising overall survival SURVIVAL demonstrated in early studies, median OS 42.3 months1 Simple 2-dose regim
Slide 14: TLX250: Targeting ccRCC, pan-cancer potential
TLX250: Targeting ccRCC, pan-cancer potential Positioned to be first CAIX-targeting rADC to market TLX250-CDx detection of CAIX expressing tumors • Promising target expressed in PET +ve CT1 Fused PET/CT >90% of ccRCC (most common kidney cancer) and range of solid tumors2 Renal cell carcinoma • Valid
Slide 15: TLX101: Impacting glioblastoma
TLX101: Impacting glioblastoma A compelling direction for an unmet medical need TLX101 scan showing • Patient need: Glioblastoma currently has poor outcomes with a median overall glioblastoma uptake1 survival of 12-15 months3, 5-year survival of 4.7% • TLX101 granted orphan drug designation in the U
Slide 16: TLX090: Next generation for metastatic cancer
TLX090: Next generation for metastatic cancer Pain management and palliative treatment of osteoblastic bone metastases • Patient need: Relief from pain due to bony (osteoblastic) metastases needs new, SPECT/CT scan of cost-effective solutions. Current standard of care relies heavily on opioids, crea
Slide 17: TLX400: Fibroblast activation protein (FAP) targeting
TLX400: Fibroblast activation protein (FAP) targeting Next-generation asset, pan-cancer potential FAP therapy (TLX400) in RAI-R1- • Fibroblast activation protein (FAP) is one of the targets with thyroid cancer2 the most potential in nuclear medicine – expressed in over 90% of epithelial cancers3 • N
Slide 18: Precision Medicine
Precision Medicine 18
Slide 19: Precision medicine strategy
Precision medicine strategy Expanding Telix’s industry-leading precision medicine franchise New product launches1 Global expansion Grow market share and patient reach Multiple Preparation for U.S. • Illuccix® approvals • Continued focus on launches in 2025 for expected in EU, UK, innovation and comm
Slide 20: Global product expansion
Global product expansion Transition to a global, multi-product commercial product portfolio is underway PSMA Prostate CAIX Kidney LAT Brain • Gozellix: follow-on PSMA • Zircaix BLA filed with the FDA • NDA accepted by FDA; granted product, PDUFA goal date 24 December 20241 priority review, PDUFA go
Slide 21: Indication expansion to grow the opportunity
Indication expansion to grow the opportunity Driving clinical utility and differentiation across the patient journey in prostate cancer 1) Current indication: Initial 2) Current indication: 3) Current indication: staging prior to definitive therapy Suspected recurrence Selection for RLT1 Other tumor
Slide 22: Sustained leadership in prostate cancer imaging
Sustained leadership in prostate cancer imaging PSMA targeting is solved, technology will further unleash the power of imaging Enhancing imaging with AI Proprietary tools and clinical decision support software. Telix + SubtlePET, a virtual upgrade for any PET scanner Reach access “deserts” Gozellix®
Slide 23: Zircaix: Practice-changing solution for renal imaging
Zircaix®: “Practice-changing” solution for renal imaging ZIRCON imaging data validates target in ccRCC1,2 • Sensitivity of 86% and specificity of 87%, PPV3 of 93% in patients with cT1 indeterminate renal mass (≤7cm) • High diagnostic performance for detection and characterization of small and very s
Slide 24: Pixclara: Preparation for 2025 commercial launch
Pixclara®: Preparation for 2025 commercial launch Unmet need for delineating progressive disease from treatment-induced changes • U.S. total addressable market: 95,000+ scans across multiple ROC3 analysis of 80 clinical indications; market value US$475-665M1 patients with grade 3/4 glioma or brain m
Slide 25: Telix Manufacturing Solutions
Telix Manufacturing Solutions 25
Slide 26: Global manufacturing capability is key to delivery
Global manufacturing capability is key to delivery Ensuring confidence through world-class manufacturing and supply chain capabilities Our strategy is based on: Last mile Harnessing resources delivery, and expertise patient Conjugation confidence Scaling to meet rapid growth and demand Isotope Radio
Slide 27: Global patient reach
Global patient reach A strategy combining partnerships and owned assets Telix Partners RLS acquisition subject to completion. Expected early Q1 2025. 27
Slide 28: U.S. coverage
U.S. coverage Multiple channels ensure patient access and industry leading reliability Strategic partner pharmacy network Telix-owned network RLS acquisition subject to completion. Expected early Q1 2025. 28
Slide 29: More than bricks and mortar – talent and expertise
More than “bricks and mortar” – talent and expertise Global reach, international talent pool and an unrivalled R&D platform TMS (Telix Mfg Solutions) California, U.S. Vancouver, Texas, U.S. U.S. (Nationwide) Brussels, Canada Belgium RLS acquisition subject to completion. Expected early Q1 2025. 29
Slide 30: Delivering in 2025
Delivering in 2025 30
Slide 31: Multiple drivers of value creation
Multiple drivers of value creation Foundations in place for rapid and sustainable growth Commercial Pipeline Ensuring 2025 A transformative Growth Development Patient Access • Proven track • Multiple near-term • Industry-leading year for Telix record of delivery catalysts supply chain, production •
Slide 32: Delivering the plan
Delivering the plan Catalysts Commercial portfolio and Progress late-stage Advance next generation World-class geographic expansion therapeutic pipeline radiopharmaceuticals manufacturing H1 2025 H2 2025 ProstACT GLOBAL (TLX591) Zircaix1 anticipated FDA approval ZOLAR (TLX300) patient dosing decisio
Slide 33: Contact
Contact : Belinda White Investor Relations belinda.white@telixpharma.com Illustration showing TLX250 binding to carbonic anhydrase IX and internalization
Telix Pharmaceuticals — JP Morgan 43rd Annual Healthcare Conference 2025 on 6ix